Biofourmis hires two experienced pharma executives as it looks to accelerate its global expansion

August 26, 2019
Digital Transformation More...
by Nardev Ramanathan
Average importance

Biofourmis' announcement of two pharma veteran hires comes close on the heels of its partnership with the U.S. FDA and other major institutions to use digital therapeutics and wearables to study clinical endpoints in drug trials. Peter Braun and John Varaklis both bring a combined half a century of pharma experience in global strategy and clinical operations, respectively. Barely half a decade old, Biofourmis has shown rapid momentum in acquiring funding and forging strategic partnerships to validate its algorithms. Lux has shared the importance of strategic pharma partnerships, but strategic pharma hires also boost internal strategy to position digital therapeutics on equal footing with a traditional pharma product. 

For the original news article, click here .

Further Reading

Novartis to acquire digital therapeutic Amblyotech for treating "lazy eye"

News Commentary | April 23, 2020

The acquisition of Amblyotech for the treatment of "lazy eye" will add to Novartis' involvement with digital therapeutics. Despite a highly publicized ending of a distribution agreement between Novartis generics division Sandoz and Pear Therapeutics, Novartis has continued to work with Pear on a ... Not part of subscription

Swedish pharmaceutical company launches two digital therapeutics in U.S. for treating opioid disorder

News Commentary | July 17, 2020

Historically, digital therapeutics have been developed by independent startups – and shared with pharmaceutical companies through partnership agreements. However, as these therapies become more commonplace, pharmaceuticals are developing more digital therapeutics to complement their chemical ... To read more, click here.

AI-enabled drug discovery company Recursion Pharmaceuticals raises $239 million and announces partnership with Bayer

News Commentary | September 15, 2020

Recursion's Series D funding comes a little more than a year after its $121 million Series C round. Since its previous funding, the company claims to have doubled the number of preclinical and clinical programs in its pipeline and doubled the size of its proprietary database. Altogether, the company... Not part of subscription